Recent Updates
Recently added Catalysts

G-Pen Mini

Phase 2

Diabetes Mellitus, Type 1 | Small molecule | Metabolic |Xeris Biopharma Holdings, Inc.|Last Updated: Mar 3, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment42
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02660242The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 DiabetesPHASE2 COMPLETED 16Jan 1, 2016Feb 15, 2017Mar 3, 20202 United States
NCT02411578Mini-Dose Glucagon to Treat Non-Severe HypoglycemiaPHASE2 COMPLETED 26Sep 1, 2015May 1, 2016Mar 3, 20205 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Glycemic Response During Exercise and Early Recovery
0 to 75 minutes following exercise initiation (0, 5, 10, 15, 25, 35, 45, 50, 55, 60, 75 min)

Comparison of glycemic response (from blood glucose) during exercise and early recovery between each exercise strategy.

Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment
30 minutes
Secondary Endpoints
Number of Participants With Hypoglycemia (<70 mg/dL) During Exercise and Early Recovery
0 to 75 minutes following exercise initiation
Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery
0 to 75 minutes following exercise initiation
Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose
90 min after the standard meal until 1200 noon the day after each exercise session
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposePREVENTION
Treatment Arms
ArmTypeDescription
ControlNO_INTERVENTIONNo basal insulin adjustment, no carbohydrate intake (until glucose drops \<70 mg/dL).
Basal insulin reductionACTIVE_COMPARATORBasal insulin reduction to 50% five minutes before the start of exercise.
Glucose TabsACTIVE_COMPARATORDextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
G-Pen Mini™ (glucagon injection)EXPERIMENTALGlucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
Interventions
NameTypeDescription
G-Pen Mini™ (glucagon injection)DRUGGlucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
Glucose TabsOTHERDextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
Basal Insulin ReductionOTHERBasal insulin reduction to 50% 5 minutes before the start of exercise.
Glucose TabletsOTHER1st BG check, 1st treatment 1. BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates 2. BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates 15 min later, 2nd BG check, 2nd treatment 1. BG is 60-69 mg/dl, no treatment 2. BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates 3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon 30 minutes later, 3rd BG check, 3rd treatment 1. BG is \>=70, no treatment 2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon (5 grams of fast-acting carbohydrates (D-Glucose) per tablet)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 64 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: 1. Clinical diagnosis of presumed autoimmune type 1 diabetes, receiving daily insulin 2. Age 18-\<65 years 3. Duration of T1D ≥ 2 years 4. Random C-peptide \< 0.6 ng/ml 5. Using continuous subcutaneous insulin infusion (CSII; insulin pump) for at least 6 months, with no plans to...

Countries:United States
Unlock Eligibility Criteria